Stockscreener 앱 받기
11.78
4.62%
0.5297
전일 마감가:
$11.25
열려 있는:
$11.43
하루 거래량:
19,255
Relative Volume:
0.02
시가총액:
$900.57M
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-4.076
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
-5.23%
1개월 성능:
-1.75%
6개월 성능:
-41.03%
1년 성능:
-47.92%
1일 변동 폭
$11.26
$11.92
1주일 범위
$11.12
$12.56
52주 변동 폭
$8.18
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.78 | 928.86M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.09 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.43 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.18 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.51 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.4%What's Next? - MarketBeat
What drives Nurix Therapeutics Inc. stock priceTremendous wealth creation - jammulinksnews.com
Nurix Therapeutics Inc. Stock Analysis and ForecastJaw-dropping returns - printweek.in
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
Is Nurix Therapeutics Inc. a good long term investmentSuperior stock selection - jammulinksnews.com
Massachusetts Financial Services Co. MA Sells 24,398 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
What analysts say about Nurix Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst - MarketBeat
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress By Investing.com - Investing.com South Africa
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress - Investing.com Australia
When (NRIX) Moves Investors should Listen - news.stocktradersdaily.com
Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright - Yahoo Finance
NRIX: Morgan Stanley Lowers Price Target for Nurix Therapeutics - GuruFocus
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts - Benzinga
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $34.00 at HC Wainwright - MarketBeat
H.C. Wainwright Adjusts Price Target for Nurix Therapeutics (NRI - GuruFocus
Navigating Nurix Therapeutics' Early-Stage Biotech Landscape: A Strategic SWOT Analysis - AInvest
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $30.00 by Analysts at Oppenheimer - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results - MarketBeat
Nurix Therapeutics: The BTK Disruptor With Undervalued Upside Potential - AInvest
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics' (NRIX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 7.8% After Earnings Beat - MarketBeat
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Piper Sandler Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Nurix Therapeutics (NRIX) Stock Target Price Lowered by UBS Anal - GuruFocus
UBS Group Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $26.00 - MarketBeat
Mixed Moves In Health And Biotech Funds - Finimize
Oppenheimer Adjusts Price Target on Nurix Therapeutics to $30 From $32, Maintains Outperform Rating - MarketScreener
Stephens & Co. Reiterates Overweight Rating for Nurix Therapeuti - GuruFocus
UBS Adjusts Price Target on Nurix Therapeutics to $26 From $30, Keeps Buy Rating - MarketScreener
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX) | - GuruFocus
Nurix Therapeutics (NRIX) Target Price Adjusted by UBS | NRIX St - GuruFocus
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.61%
0.41%
자본화:
|
볼륨(24시간):